Previous 10 | Next 10 |
With the US Q3 earnings season just getting started, there are a few biotech stocks that present an exciting opportunity for value investors. Some of these stocks look significantly undervalued after a decline in their stock prices. Regeneron Pharmaceuticals Regeneron Pharmaceut...
Biogen is one of the leading providers of medicines used for the treatment of multiple sclerosis, spinal muscular atrophy. Biogen's gross margin is around 83.4%, significantly higher than the medical industry average and one of the highest among the top 20 pharmaceutical companies in ...
Improvement in measurements of overall quality of life, functioning and general well-being achieved at Day 15 and sustained at Day 42 Consistent and differentiated safety and tolerability profile seen across clinical programs Sage to host conference call on October 4, ...
Effort embodies Sage’s long-term commitment to investing in People, Patients, Planet and Community Sage Therapeutics (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitati...
Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced the appointment of Chris Benecchi as Chief Commercial Officer. In his new r...
Sage Therapeutics, Inc. (Nasdaq:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Trac...
The WHO predicts that depression will be the biggest problem in the world during the next decade and beyond. GH Research had a rather successful IPO on the 24th of June. Investing in biotech may be the way to go for investors looking for large gains over the long term. For f...
Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will present at the following upcoming investor conf...
Image source: The Motley Fool. Sage Therapeutics Inc (NASDAQ: SAGE) Q2 2021 Earnings Call Aug 3, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Sage Therapeutics Inc (SAGE) Q2 2021 Earnings Call Transcript
SAGE Therapeutics, Inc. (SAGE) Q2 2021 Earnings Conference Call August 03, 2021, 08:00 ET Company Participants Jeff Boyle - Investor Contact Barry Greene - President, CEO & Director Stephen Kanes - Chief Medical Officer Kimi Iguchi - CFO & Treasurer Conference Call Participants Paul M...
News, Short Squeeze, Breakout and More Instantly...
Sage Therapeutics Inc. Company Name:
SAGE Stock Symbol:
NASDAQ Market:
Sage Therapeutics Inc. Website:
Achieved $7.4 million in ZURZUVAE™ (zuranolone) collaboration revenue during the second quarter of 2024 (50% of the net revenues recorded by Biogen), representing 19% growth from the first quarter More than 1,400 prescriptions shipped and delivered during the second quarter of 2024...
- SAGE-324 (BIIB124) did not demonstrate a statistically significant dose-response relationship on the primary endpoint in participants with essential tremor - No statistically significant differences were demonstrated between any dose of SAGE-324 and placebo in the change from baseline...
Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that it will host a live webcast on Wednesday, July 31, 2024 at 4:30 p.m. ET to review second quarter 2024 financial results and discuss recent business ...